U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H31O4.K
Molecular Weight 410.5881
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRORENOATE POTASSIUM

SMILES

[K+].C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C5=CC(=O)CC[C@]35C)[C@@H]1CC[C@@]2(O)CCC([O-])=O

InChI

InChIKey=NLSAMWIBIQWHTK-CZKUEYQYSA-M
InChI=1S/C23H32O4.K/c1-21-7-3-13(24)11-18(21)14-12-15(14)20-16(21)4-8-22(2)17(20)5-9-23(22,27)10-6-19(25)26;/h11,14-17,20,27H,3-10,12H2,1-2H3,(H,25,26);/q;+1/p-1/t14-,15+,16+,17+,20-,21-,22+,23-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C23H31O4
Molecular Weight 371.4898
Charge -1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Prorenoate Potassium is a water-soluble synthetic aldosterone antagonist patented by Merck and Co., Inc. as an antihypertensive agent. In preclinical studies a significant natriuretic response was obtained at dosages of 1 mg/kg and approximately 1.8 mg/kg in the dog and rat, respectively. Prorenoate is relatively inactive at the renal level in adrenalectomized rats without mineralocorticoid replacement. Prorenoate possesses no more than 2% of the natriuretic activity of hydrochlorothiazide in the intact animal. Clearance studies in dogs indicate a direct renal tubular site of interaction between prorenoate and aldosterone independent of changes in renal hemodynamics. The natriuretic response occurred within 100 minutes after a single oral dose and was sustained for at least 7 hours. In clinical trials Prorenoate reversing the renal effects of the synthetic mineralocorticoid fludrocortisone in healthy individuals. Prorenoate was significantly more potent in retaining K+ than in increasing Na+ excretion.

Originator

Approval Year

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
40 mg as single oral dose
Route of Administration: Oral
Substance Class Chemical
Record UNII
T2D4XUS623
Record Status Validated (UNII)
Record Version